{"id":4489,"date":"2024-10-07T13:35:38","date_gmt":"2024-10-07T11:35:38","guid":{"rendered":"https:\/\/cnatm-1.betapage.de\/?p=4489"},"modified":"2025-02-05T13:00:00","modified_gmt":"2025-02-05T12:00:00","slug":"2024-nobel-prize-for-microrna","status":"publish","type":"post","link":"https:\/\/cnatm.de\/en\/2024-nobel-prize-for-microrna\/","title":{"rendered":"2024 Nobel Prize for microRNA"},"content":{"rendered":"<div data-elementor-type=\"wp-post\" data-elementor-id=\"4489\" class=\"elementor elementor-4489\" data-elementor-settings=\"{&quot;ha_cmc_init_switcher&quot;:&quot;no&quot;}\" data-elementor-post-type=\"post\">\n\t\t\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-3be878d2 elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"3be878d2\" data-element_type=\"section\" data-e-type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-11a6d38e\" data-id=\"11a6d38e\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-6aff34c7 elementor-widget elementor-widget-text-editor\" data-id=\"6aff34c7\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<h2 contenteditable=\"true\" data-elementor-setting-key=\"title\" data-pen-placeholder=\"Eingabe hier...\"><span dir=\"ltr\">2024 Nobel Prize awarded to the discovery of microRNA<\/span><\/h2><p><span dir=\"ltr\"><br \/>Victor Ambros and Gary Ruvkun have been awarded the 2024 Nobel Prize for their discovery of the first microRNA, lin-4, in C. elegans.<br \/>This is the second consecutive Nobel Prize for nucleic acids, following the 2023 Nobel Prize for Katalin Karik\u00f3 and Drew Weissmann for their work on\nmRNA technology. The development of nucleic acid-based therapeutics is the goal of the Cluster for Nucleic Acid Therapeutics Munich (CNATM).<br \/>In CNATM leading academic groups and 14 biotech companies are working together to achieve this goal. Several CNATM partners are focusing on microRNA-based therapeutics (rnatics GmbH, Secarna Pharmaceuticals GmbH, Engelhardt Group at the Institut for Pharmacology and Toxikology at TUM, Yildirim Group at the Helmholtz M\u00fcnchen).<br \/><\/span><\/p><p><span dir=\"ltr\"><a href=\"https:\/\/www.nobelprize.org\/prizes\/medicine\/2024\/press-release\/\">Read more<\/a><br \/><\/span><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-7ce981b elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"7ce981b\" data-element_type=\"section\" data-e-type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-ebc2e1d\" data-id=\"ebc2e1d\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-8f6d26a elementor-widget elementor-widget-spacer\" data-id=\"8f6d26a\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"spacer.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<div class=\"elementor-spacer\">\n\t\t\t<div class=\"elementor-spacer-inner\"><\/div>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<\/div>","protected":false},"excerpt":{"rendered":"<p>Nobelpreis 2024 f\u00fcr die Entdeckung der microRNA Victor Ambros und Gary Ruvkun erhalten den Nobelpreis 2024 f\u00fcr ihre Entdeckung der ersten microRNA, lin-4, in C. elegans.Dies ist der zweite Nobelpreis f\u00fcr Nukleins\u00e4uren in Folge nach dem Nobelpreis 2023 f\u00fcr Katalin Karik\u00f3 und Drew Weissmann f\u00fcr ihre Arbeiten zur mRNA-Technologie. Die Entwicklung von Nukleins\u00e4ure-basierten Therapeutika ist [&hellip;]<\/p>\n","protected":false},"author":11,"featured_media":4358,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[62],"tags":[],"class_list":["post-4489","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>2024 Nobel Prize for microRNA - CNATM<\/title>\n<meta name=\"description\" content=\"Victor Ambros and Gary Ruvkun have been awarded the 2024 Nobel Prize for theirdiscovery of the first microRNA, lin-4, in C. elegans. This is the second consecutive Nobel Prize for nucleic acids, following the 2023 Nobel Prize for Katalin Karik\u00f3 and Drew Weissmann for their work onmRNA technology. The development of nucleic acid-based therapeutics is the goal of the Cluster for Nucleic Acid Therapeutics Munich (CNATM). In CNATM leading academic groups and 14 biotech companies are working together to achieve this goal. Several CNATM partners are focusing on microRNA-based therapeutics (rnatics GmbH, Secarna Pharmaceuticals GmbH, Engelhardt Group at the Institut for Pharmacology and Toxikology at TUM, Yildirim Group at the Helmholtz M\u00fcnchen).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cnatm.de\/en\/2024-nobel-prize-for-microrna\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"2024 Nobel Prize for microRNA - CNATM\" \/>\n<meta property=\"og:description\" content=\"Victor Ambros and Gary Ruvkun have been awarded the 2024 Nobel Prize for theirdiscovery of the first microRNA, lin-4, in C. elegans. This is the second consecutive Nobel Prize for nucleic acids, following the 2023 Nobel Prize for Katalin Karik\u00f3 and Drew Weissmann for their work onmRNA technology. The development of nucleic acid-based therapeutics is the goal of the Cluster for Nucleic Acid Therapeutics Munich (CNATM). In CNATM leading academic groups and 14 biotech companies are working together to achieve this goal. Several CNATM partners are focusing on microRNA-based therapeutics (rnatics GmbH, Secarna Pharmaceuticals GmbH, Engelhardt Group at the Institut for Pharmacology and Toxikology at TUM, Yildirim Group at the Helmholtz M\u00fcnchen).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cnatm.de\/en\/2024-nobel-prize-for-microrna\/\" \/>\n<meta property=\"og:site_name\" content=\"CNATM\" \/>\n<meta property=\"article:published_time\" content=\"2024-10-07T11:35:38+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-02-05T12:00:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cnatm.de\/wp-content\/uploads\/2024\/08\/News_Beitragsbild.png\" \/>\n\t<meta property=\"og:image:width\" content=\"945\" \/>\n\t<meta property=\"og:image:height\" content=\"445\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Patrizia Torelli\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Patrizia Torelli\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/cnatm.de\\\/2024-nobel-prize-for-microrna\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/cnatm.de\\\/2024-nobel-prize-for-microrna\\\/\"},\"author\":{\"name\":\"Patrizia Torelli\",\"@id\":\"https:\\\/\\\/cnatm.de\\\/#\\\/schema\\\/person\\\/f2fc8eccad93916c1b891b5fef1ac19e\"},\"headline\":\"2024 Nobel Prize for microRNA\",\"datePublished\":\"2024-10-07T11:35:38+00:00\",\"dateModified\":\"2025-02-05T12:00:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/cnatm.de\\\/2024-nobel-prize-for-microrna\\\/\"},\"wordCount\":119,\"publisher\":{\"@id\":\"https:\\\/\\\/cnatm.de\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/cnatm.de\\\/2024-nobel-prize-for-microrna\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cnatm.de\\\/wp-content\\\/uploads\\\/2024\\\/08\\\/News_Beitragsbild.png\",\"articleSection\":[\"News\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/cnatm.de\\\/2024-nobel-prize-for-microrna\\\/\",\"url\":\"https:\\\/\\\/cnatm.de\\\/2024-nobel-prize-for-microrna\\\/\",\"name\":\"2024 Nobel Prize for microRNA - CNATM\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/cnatm.de\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/cnatm.de\\\/2024-nobel-prize-for-microrna\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/cnatm.de\\\/2024-nobel-prize-for-microrna\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cnatm.de\\\/wp-content\\\/uploads\\\/2024\\\/08\\\/News_Beitragsbild.png\",\"datePublished\":\"2024-10-07T11:35:38+00:00\",\"dateModified\":\"2025-02-05T12:00:00+00:00\",\"description\":\"Victor Ambros and Gary Ruvkun have been awarded the 2024 Nobel Prize for theirdiscovery of the first microRNA, lin-4, in C. elegans. This is the second consecutive Nobel Prize for nucleic acids, following the 2023 Nobel Prize for Katalin Karik\u00f3 and Drew Weissmann for their work onmRNA technology. The development of nucleic acid-based therapeutics is the goal of the Cluster for Nucleic Acid Therapeutics Munich (CNATM). In CNATM leading academic groups and 14 biotech companies are working together to achieve this goal. Several CNATM partners are focusing on microRNA-based therapeutics (rnatics GmbH, Secarna Pharmaceuticals GmbH, Engelhardt Group at the Institut for Pharmacology and Toxikology at TUM, Yildirim Group at the Helmholtz M\u00fcnchen).\",\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/cnatm.de\\\/2024-nobel-prize-for-microrna\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/cnatm.de\\\/2024-nobel-prize-for-microrna\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cnatm.de\\\/wp-content\\\/uploads\\\/2024\\\/08\\\/News_Beitragsbild.png\",\"contentUrl\":\"https:\\\/\\\/cnatm.de\\\/wp-content\\\/uploads\\\/2024\\\/08\\\/News_Beitragsbild.png\",\"width\":945,\"height\":445},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/cnatm.de\\\/#website\",\"url\":\"https:\\\/\\\/cnatm.de\\\/\",\"name\":\"CNATM\",\"description\":\"Cluster for Nucleic Acid Therapeutics Munich\",\"publisher\":{\"@id\":\"https:\\\/\\\/cnatm.de\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/cnatm.de\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/cnatm.de\\\/#organization\",\"name\":\"CNATM\",\"url\":\"https:\\\/\\\/cnatm.de\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/cnatm.de\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/cnatm.de\\\/wp-content\\\/uploads\\\/2022\\\/02\\\/CNATM-Logo-mit-Zusatz-RGB-bunt-schwarz.jpg\",\"contentUrl\":\"https:\\\/\\\/cnatm.de\\\/wp-content\\\/uploads\\\/2022\\\/02\\\/CNATM-Logo-mit-Zusatz-RGB-bunt-schwarz.jpg\",\"width\":2362,\"height\":479,\"caption\":\"CNATM\"},\"image\":{\"@id\":\"https:\\\/\\\/cnatm.de\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/cnatm.de\\\/#\\\/schema\\\/person\\\/f2fc8eccad93916c1b891b5fef1ac19e\",\"name\":\"Patrizia Torelli\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/87ab0132dfbaaa804847124811e093cdf95fa3b96905aba129559c779a1ff8eb?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/87ab0132dfbaaa804847124811e093cdf95fa3b96905aba129559c779a1ff8eb?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/87ab0132dfbaaa804847124811e093cdf95fa3b96905aba129559c779a1ff8eb?s=96&d=mm&r=g\",\"caption\":\"Patrizia Torelli\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"2024 Nobel Prize for microRNA - CNATM","description":"Victor Ambros and Gary Ruvkun have been awarded the 2024 Nobel Prize for theirdiscovery of the first microRNA, lin-4, in C. elegans. This is the second consecutive Nobel Prize for nucleic acids, following the 2023 Nobel Prize for Katalin Karik\u00f3 and Drew Weissmann for their work onmRNA technology. The development of nucleic acid-based therapeutics is the goal of the Cluster for Nucleic Acid Therapeutics Munich (CNATM). In CNATM leading academic groups and 14 biotech companies are working together to achieve this goal. Several CNATM partners are focusing on microRNA-based therapeutics (rnatics GmbH, Secarna Pharmaceuticals GmbH, Engelhardt Group at the Institut for Pharmacology and Toxikology at TUM, Yildirim Group at the Helmholtz M\u00fcnchen).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cnatm.de\/en\/2024-nobel-prize-for-microrna\/","og_locale":"en_US","og_type":"article","og_title":"2024 Nobel Prize for microRNA - CNATM","og_description":"Victor Ambros and Gary Ruvkun have been awarded the 2024 Nobel Prize for theirdiscovery of the first microRNA, lin-4, in C. elegans. This is the second consecutive Nobel Prize for nucleic acids, following the 2023 Nobel Prize for Katalin Karik\u00f3 and Drew Weissmann for their work onmRNA technology. The development of nucleic acid-based therapeutics is the goal of the Cluster for Nucleic Acid Therapeutics Munich (CNATM). In CNATM leading academic groups and 14 biotech companies are working together to achieve this goal. Several CNATM partners are focusing on microRNA-based therapeutics (rnatics GmbH, Secarna Pharmaceuticals GmbH, Engelhardt Group at the Institut for Pharmacology and Toxikology at TUM, Yildirim Group at the Helmholtz M\u00fcnchen).","og_url":"https:\/\/cnatm.de\/en\/2024-nobel-prize-for-microrna\/","og_site_name":"CNATM","article_published_time":"2024-10-07T11:35:38+00:00","article_modified_time":"2025-02-05T12:00:00+00:00","og_image":[{"width":945,"height":445,"url":"https:\/\/cnatm.de\/wp-content\/uploads\/2024\/08\/News_Beitragsbild.png","type":"image\/png"}],"author":"Patrizia Torelli","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Patrizia Torelli","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/cnatm.de\/2024-nobel-prize-for-microrna\/#article","isPartOf":{"@id":"https:\/\/cnatm.de\/2024-nobel-prize-for-microrna\/"},"author":{"name":"Patrizia Torelli","@id":"https:\/\/cnatm.de\/#\/schema\/person\/f2fc8eccad93916c1b891b5fef1ac19e"},"headline":"2024 Nobel Prize for microRNA","datePublished":"2024-10-07T11:35:38+00:00","dateModified":"2025-02-05T12:00:00+00:00","mainEntityOfPage":{"@id":"https:\/\/cnatm.de\/2024-nobel-prize-for-microrna\/"},"wordCount":119,"publisher":{"@id":"https:\/\/cnatm.de\/#organization"},"image":{"@id":"https:\/\/cnatm.de\/2024-nobel-prize-for-microrna\/#primaryimage"},"thumbnailUrl":"https:\/\/cnatm.de\/wp-content\/uploads\/2024\/08\/News_Beitragsbild.png","articleSection":["News"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/cnatm.de\/2024-nobel-prize-for-microrna\/","url":"https:\/\/cnatm.de\/2024-nobel-prize-for-microrna\/","name":"2024 Nobel Prize for microRNA - CNATM","isPartOf":{"@id":"https:\/\/cnatm.de\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cnatm.de\/2024-nobel-prize-for-microrna\/#primaryimage"},"image":{"@id":"https:\/\/cnatm.de\/2024-nobel-prize-for-microrna\/#primaryimage"},"thumbnailUrl":"https:\/\/cnatm.de\/wp-content\/uploads\/2024\/08\/News_Beitragsbild.png","datePublished":"2024-10-07T11:35:38+00:00","dateModified":"2025-02-05T12:00:00+00:00","description":"Victor Ambros and Gary Ruvkun have been awarded the 2024 Nobel Prize for theirdiscovery of the first microRNA, lin-4, in C. elegans. This is the second consecutive Nobel Prize for nucleic acids, following the 2023 Nobel Prize for Katalin Karik\u00f3 and Drew Weissmann for their work onmRNA technology. The development of nucleic acid-based therapeutics is the goal of the Cluster for Nucleic Acid Therapeutics Munich (CNATM). In CNATM leading academic groups and 14 biotech companies are working together to achieve this goal. Several CNATM partners are focusing on microRNA-based therapeutics (rnatics GmbH, Secarna Pharmaceuticals GmbH, Engelhardt Group at the Institut for Pharmacology and Toxikology at TUM, Yildirim Group at the Helmholtz M\u00fcnchen).","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cnatm.de\/2024-nobel-prize-for-microrna\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cnatm.de\/2024-nobel-prize-for-microrna\/#primaryimage","url":"https:\/\/cnatm.de\/wp-content\/uploads\/2024\/08\/News_Beitragsbild.png","contentUrl":"https:\/\/cnatm.de\/wp-content\/uploads\/2024\/08\/News_Beitragsbild.png","width":945,"height":445},{"@type":"WebSite","@id":"https:\/\/cnatm.de\/#website","url":"https:\/\/cnatm.de\/","name":"CNATM","description":"Cluster for Nucleic Acid Therapeutics Munich","publisher":{"@id":"https:\/\/cnatm.de\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cnatm.de\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/cnatm.de\/#organization","name":"CNATM","url":"https:\/\/cnatm.de\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cnatm.de\/#\/schema\/logo\/image\/","url":"https:\/\/cnatm.de\/wp-content\/uploads\/2022\/02\/CNATM-Logo-mit-Zusatz-RGB-bunt-schwarz.jpg","contentUrl":"https:\/\/cnatm.de\/wp-content\/uploads\/2022\/02\/CNATM-Logo-mit-Zusatz-RGB-bunt-schwarz.jpg","width":2362,"height":479,"caption":"CNATM"},"image":{"@id":"https:\/\/cnatm.de\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/cnatm.de\/#\/schema\/person\/f2fc8eccad93916c1b891b5fef1ac19e","name":"Patrizia Torelli","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/87ab0132dfbaaa804847124811e093cdf95fa3b96905aba129559c779a1ff8eb?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/87ab0132dfbaaa804847124811e093cdf95fa3b96905aba129559c779a1ff8eb?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/87ab0132dfbaaa804847124811e093cdf95fa3b96905aba129559c779a1ff8eb?s=96&d=mm&r=g","caption":"Patrizia Torelli"}}]}},"_links":{"self":[{"href":"https:\/\/cnatm.de\/en\/wp-json\/wp\/v2\/posts\/4489","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cnatm.de\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cnatm.de\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cnatm.de\/en\/wp-json\/wp\/v2\/users\/11"}],"replies":[{"embeddable":true,"href":"https:\/\/cnatm.de\/en\/wp-json\/wp\/v2\/comments?post=4489"}],"version-history":[{"count":20,"href":"https:\/\/cnatm.de\/en\/wp-json\/wp\/v2\/posts\/4489\/revisions"}],"predecessor-version":[{"id":5796,"href":"https:\/\/cnatm.de\/en\/wp-json\/wp\/v2\/posts\/4489\/revisions\/5796"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cnatm.de\/en\/wp-json\/wp\/v2\/media\/4358"}],"wp:attachment":[{"href":"https:\/\/cnatm.de\/en\/wp-json\/wp\/v2\/media?parent=4489"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cnatm.de\/en\/wp-json\/wp\/v2\/categories?post=4489"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cnatm.de\/en\/wp-json\/wp\/v2\/tags?post=4489"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}